Skip to main
GMED

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical is continuing to see strong sales and earnings growth, driven by their popular musculoskeletal solutions products and international expansion. This growth, combined with their commitment to innovation and strategic partnerships, sets them up for long-term success in the medical device industry. With a steady financial position and positive market sentiment, the company has the potential to outperform and generate returns for investors.

Bears say

Globus Medical is a medical device company with a strong presence in the domestic market and a significant international presence as well. The company has demonstrated strong earnings growth and margin improvement, driven by organic revenue growth and gross margin expansion. However, there are several risks to consider, including slower growth in the spine market, potential revenue dis-synergies following recent mergers, and lower than expected sales of enabling technologies. Additionally, in a downside scenario, slower uptake of robotics and delays in recon robotics could impact the company's margins. While guidance suggests potential upside, there is still potential for the company to beat top-line expectations and drive further earnings growth. Ultimately, our outlook remains negative due to competitive pressures and potential risks that could impact growth and margins.

Globus Medical (GMED) has been analyzed by 12 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 12 analysts, Globus Medical (GMED) has a Buy consensus rating as of Jul 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $101.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $101.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.